Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663703 | 1.00 | GAA (0.59) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL3399797 | 1.00 | GAA (0.59) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL14154101 | 1.00 | GAA (0.59) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL16736608 | 0.90 | GAA (0.58) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL16736849 | 0.90 | TSHR (0.57) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL487428 | 0.86 | GAA (0.67) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL339877 | 0.83 | GAA (0.63) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL683547 | 0.83 | HSD17B10 (0.69) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL3152462 | 0.82 | GAA (0.62) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL9336626 | 0.82 | TSHR (0.72) | GAAALDH1A1USP2PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0989164-B1 | N,N-Dialkylaniline azo dye solutions | MORTON INT INC (US) | 2001-12-12 | — | — | EP | claimed |
| JP-63199247-A | — | — | None | — | — | JP | disclosed |
| CN-113337170-B | Curable composition, cured product, near infrared absorbing filter, and method for producing same | 东京应化工业株式会社 | 2024-04-05 | — | — | CN | disclosed |
| CN-117327362-A | Curable resin composition | 东京应化工业株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-117215149-A | Photosensitive resin composition | 东京应化工业株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-113337170-A | Curable composition, cured product, near-infrared absorption filter, and method for producing same | 东京应化工业株式会社 | 2021-09-03 | — | — | CN | disclosed |
| CN-107586255-A | A kind of method for preparing alkyl phenol using catalyst with base of molybdenum catalyzed conversion phenolic compound | 天津大学 | 2018-01-16 | — | — | CN | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS, INC. | 2011-01-27 | — | — | US | disclosed |
| EP-2146946-B1 | (-)- stereoisomer of 2,6-di-sec-butylphenol and analogs thereof | PHARMACOFORE INC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7795450-B2 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-7619097-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090030080-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-4892671-A | FUEL AND OIL ADDITIVES | CIBA-GEIGY CORPORATION (US) | 1990-01-09 | — | — | US | disclosed |
| JP-S63199247-A | LIQUID STABILIZER COMPOSITION FOR ORGANIC SUBSTANCE | ADEKA ARGUS CHEM CO LTD | 1988-08-17 | — | — | JP | disclosed |
| EP-0252007-A2 | 2-Propanol derivatives as corrosion inhibitors | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | GAA 1169/4885ALDH1A1 852/4885USP2 1312/4885 |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | GAA 3893/4885ALDH1A1 3725/4885USP2 4127/4885 |
| US-20090030080-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | GAA 3893/4885ALDH1A1 3725/4885USP2 4127/4885 |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | GAA 3893/4885ALDH1A1 3725/4885USP2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.